Table 2. Patient characteristics:... | American Society of Hematology

Table 2.

Patient characteristics: analysis B

	CHOP		CHOEP
	n	%	n	%
ALK⁺ ALCL	(n = 28)		(n = 30)
Male sex	18	64	16	53
Age at diagnosis, y
Median	43		49
Range	23-63		19-62
Ann Arbor stage
2	8	29	10	33
3-4	20	71	20	67
Elevated LDH	7	25	10	33
WHO performance score
0-2	14	50	21	70
3-4	1	4	1	3
Unknown	13	46	8	27
>1 extranodal localization	4	14	6	20
IPI score
0-2	26	93	27	90
3-5	2	7	3	10
ALK⁻ ALCL, AITL, or PTCL NOS	(n = 85)		(n = 134)
Male sex	54	64	86	64
Age at diagnosis, y
Median	55		54
Range	26-62		19-60
Subtype of T-cell NHL
ALK⁻ ALCL	14	16	31	23
ALCL NOS	0	—	1	1
PTCL NOS	25	29	54	40
AITL*	46	54	48	36
Ann Arbor stage
2	6	7	14	10
3-4	79	93	120	90
Elevated LDH	48	56	76	57
WHO performance score
0-2	38	45	78	58
3-4	0	0	4	3
Unknown	47	55	52	39
>1 extranodal localization	25	29	37	28
IPI score
0-2	52	61	92	69
3-5	33	39	42	31
ASCT	27	32	82	61

	CHOP		CHOEP
	n	%	n	%
ALK⁺ ALCL	(n = 28)		(n = 30)
Male sex	18	64	16	53
Age at diagnosis, y
Median	43		49
Range	23-63		19-62
Ann Arbor stage
2	8	29	10	33
3-4	20	71	20	67
Elevated LDH	7	25	10	33
WHO performance score
0-2	14	50	21	70
3-4	1	4	1	3
Unknown	13	46	8	27
>1 extranodal localization	4	14	6	20
IPI score
0-2	26	93	27	90
3-5	2	7	3	10
ALK⁻ ALCL, AITL, or PTCL NOS	(n = 85)		(n = 134)
Male sex	54	64	86	64
Age at diagnosis, y
Median	55		54
Range	26-62		19-60
Subtype of T-cell NHL
ALK⁻ ALCL	14	16	31	23
ALCL NOS	0	—	1	1
PTCL NOS	25	29	54	40
AITL*	46	54	48	36
Ann Arbor stage
2	6	7	14	10
3-4	79	93	120	90
Elevated LDH	48	56	76	57
WHO performance score
0-2	38	45	78	58
3-4	0	0	4	3
Unknown	47	55	52	39
>1 extranodal localization	25	29	37	28
IPI score
0-2	52	61	92	69
3-5	33	39	42	31
ASCT	27	32	82	61

Patients receiving CHOP vs CHOEP during first-line treatment.

Including T-cell NHL, follicular helper T cells.